Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02515630
Study type Interventional
Source Sierra Oncology LLC - a GSK company
Contact
Status Completed
Phase Phase 2
Start date January 29, 2016
Completion date August 15, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03441113 - Extended Access of Momelotinib in Adults With Myelofibrosis Phase 2
Completed NCT01558739 - Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Phase 4
Completed NCT00910728 - Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases Phase 1
Completed NCT02101268 - Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Phase 3
Completed NCT03136185 - Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Phase 1/Phase 2
Completed NCT04217993 - Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis Phase 2
Recruiting NCT03662126 - KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment Phase 2/Phase 3
Terminated NCT03935555 - Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Phase 1
Recruiting NCT04878003 - Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis Phase 2
Available NCT04745637 - Managed Access Programs for INC424, Ruxolitinib